Search:
Filter:
Sort:
PSM Executive Director Shabbir Safdar is speaking at the Democratic Governors Association about the threat of unregulated prescription drugs smuggled into the U.S.
Read More
Gilead Sciences filed a Lanham Act complaint against a group of companies that allegedly pushed patients into ordering non-FDA approved international medicines to lower costs in employer-sponsored health insurance plans.
Read More
Supply chain complexity means that upper payment limits and Medicare maximum fair prices will fall disproportionately on pharmacies, leading to closures that threaten patient access to care.
Read More
Although the state won FDA approval for its importation program in January 2024, it has yet to implement the program.
Read More
Medical spas and wellness clinics are operating on the edge of existing regulatory frameworks and it’s a risk to American patients.
Read More
Between November 2022 and June 2023, Amarvel Biotech sold over 200 kilograms of precursor chemicals to U.S. buyers with full knowledge that they would be used to make fentanyl.
Read More
Prescription Drug Affordability Board Activity, August 2025 Activities Summary Colorado: Colorado’s PDAB met on August 22, 2025 for to continue rulemaking to set an upper payment limit for Enbrel, during which they heard substantial public comment. They will continue this process at their next meeting on October 3. Maryland: The next PDAB meeting will be September 29, 2025. Oregon: At…
Read More
Our analysis of data from June and July revealed hundreds of pharmaceutical shipments that entered the U.S. from facilities no one would expect, including unregistered Chinese exporters and alternative medicine clinics abroad.
Read More
The warning letter was one of about 100 is a new focus on deceptive direct-to-consumer drug advertisements.
Read More
The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
Read More